Skip to main content

Table 5 Proposal for discontinuation of combined therapy with PD and HD

From: Clinical efficacy of combined therapy with peritoneal dialysis and hemodialysis

1. Insufficient solute removal (inadequate dialysis)
 β2 microglobulin >35 mg/L
 Other uremic symptoms
  Deterioration of nutritional status, decreased SGA, persistent anorexia
  ESA-hyporesponsive anemia
  Restless legs syndrome
2. Insufficient fluid removal (fluid overload)
 Higher or drug-resistant blood pressure
 Heart enlargement or pleural effusion on chest X-rays
 Persistent peripheral edema, anasarca
3. Consideration of the risk of development of EPS
 Prolonged PD duration
 Frequent PD-associated peritonitis
 Higher D/P Cr
  1. PD peritoneal dialysis, HD hemodialysis, SGA subjective global assessment, ESA erythropoiesis-stimulating agent, EPS encapsulating peritoneal sclerosis, D/P Cr dialysate-to-plasma ratio of creatinine